Method for determining lymphoma type and providing treatment
US11646099B2 · kind B2 · utility
0Cited by
0References
7Claims
0Family size
Assignees
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- British Columbia Cancer Agency
- Mayo Foundation for Medical Education and Research
- Julius-Maximilians-Universitat Wurzburg
- Boatd of Regents of the University of Nebraska
- Oslo University Hospital HF
- HOSPITAL CLÍNIC DE BARCELONA
- UNIVERSITAT DE BARCELONA
- Institut D'Investigacions Biomédiques Pi I Sunyer (IDIBAPS)
- Robert Bosch Gesellschaft feuer medizinische Forshung mbH
- Oregon Health & Science University
- City of Hope
- The Cleveland Clinic Foundation
Inventors
Key dates
| Filing date | Dec 13, 2019 |
| Grant date | May 9, 2023 |
| Priority date | — |
| Expiry date | Nov 23, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldComputer technology
- WIPO sectorElectrical engineering
Abstract
In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.